Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jul 23;19(1):655.
doi: 10.1186/s12879-019-4284-9.

Prevalence of hepatitis C infection among the general population and high-risk groups in the EU/EEA: a systematic review update

Ru Han  1   2 , Junwen Zhou  3   4 , Clément François  3   4 , Mondher Toumi  3   4
Affiliations

Prevalence of hepatitis C infection among the general population and high-risk groups in the EU/EEA: a systematic review update

Ru Han et al. BMC Infect Dis. .

Abstract

Background: Although significant improvement in efficacy measured by a sustained virological response, the high acquisition costs of direct-acting antivirals limit the access for patients and influence the costs of healthcare resource utilisation in hepatitis C. It is important to have the latest estimates of prevalence, especially in high-risk groups, for cost of illness, cost-effectiveness and budget impact studies.

Methods: Original studies on the estimates of the prevalence among general and high-risk groups in the European Union/European Economic Area (EU/EEA) were retrieved from Medline and Embase for the period from 2015 to 2018. All included studies were evaluated for risk of selection bias and summarised together in a narrative form. Results from previous reviews and updated searches were compared per country among different populations, respectively.

Results: Among the 3871 studies identified, 46 studies were included: 20 studies were used for the estimate of the general population; 3 for men who have sex with men (MSM); 6 for prisoners; and 17 for people who inject drugs (PWID). Compared with the results reported in previous systematic reviews, the updated estimates were lower than previously in most available countries. Anti-HCV general population prevalence estimates ranged from 0.54 to 1.50% by country. The highest prevalence of anti-HCV was found among PWID (range of 7.90-82.00%), followed by prisoners (7.00-41.00%), HIV-positive MSM (1.80-7.10%), HIV-negative MSM (0.20-1.80%), pregnant women (0.10-1.32%) and first-time blood donors (0.03-0.09%).

Conclusions: Our study highlights the heterogeneity in anti-HCV prevalence across different population groups in EU/EEA. The prevalence also varies widely between European countries. There are many countries that are not represented in our results, highlighting the need for the development of robust epidemiological studies.

Keywords: Europe; Hepatitis C; High-risk groups; Men who have sex with men; People who inject drugs; Prevalence; Prisoners; Systematic review.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Flow diagram of the study selection process
See this image and copyright information in PMC

References

    1. Grebely J, Dore GJ. What is killing people with hepatitis C virus infection? Semin Liver Dis. 2011;31:331–339. doi: 10.1055/s-0031-1297922. - DOI - PubMed
    1. Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection. a meta-analysis and meta-regression. Hepatology. 2008;48:418–431. doi: 10.1002/hep.22375. - DOI - PubMed
    1. Butt AA, Yan P, Lo Re V, 3rd, Rimland D, Goetz MB, Leaf D, Freiberg MS, Klein MB, Justice AC, Sherman KE. Liver fibrosis progression in hepatitis C virus infection after seroconversion. JAMA Intern Med. 2015;175:178–185. doi: 10.1001/jamainternmed.2014.6502. - DOI - PMC - PubMed
    1. World Health Organization. Global Hepatitis report, 2017. https://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/. Accessed 1 Jan 2019.
    1. Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, Vogel W, Mendes Correa MC, Hezode C, Lazaro P, et al. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat. 2014;21(Suppl 1):34–59. doi: 10.1111/jvh.12248. - DOI - PubMed

Publication types

Substances